CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Probiotix Health PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Probiotix Health PLC
Innovation Centre
Innovation Way, Heslington
YORK, YO10 5DG  United Kingdom Ticker: PBXPBX
Business Summary
ProBiotix Health plc is a United Kingdom-based life sciences company. The Company is engaged in the development of probiotics to tackle cardiovascular disease and other lifestyle conditions. Its principal product, Lactobacillus plantarum ECGC13110402 (LP-LDL), can reduce key cardiovascular risk biomarkers, such as total cholesterol, LDL (bad) cholesterol and blood pressure, by 36.7 per cent, 13.9 per cent and 5.1 per cent respectively. The Company's CholBiome products contains LP-LDL. Its products are commercialized in 60 countries. The CholBiome portfolio comprised four products, which can either be sold under the CholBiome brand or customers’ private labels: CholBiome, CholBiomeX3, CholBiomeBP and CholBiomeVH. CholBiome contains LPLDL to focus on healthy cholesterol maintenance and deliver tangible health benefits. CholBiomeX3 consists of LPLDL, Monacolin K from red yeast rice, and Vitamin B3 (niacin) to reduce cholesterol and aid overall cardiovascular health.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board AdamReynolds 61
Chief Executive Officer, Director Steen D.Andersen 1/1/2023 1/1/2023
Chief Financial Officer, Company Secretary MarkCollingbourne
Director StephenO'Hara 61 1/1/2023 1/1/2023
Non-Executive Independent Director MarcoCaspani 47

General Information
Number of Employees: 2 (As of 12/31/2022)
Outstanding Shares: 121,666,666 (As of 6/30/2023)
Stock Exchange: AQS


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024